Clinical trials: Recurrent Prostate Cancer
Prostate Cancer
Prospective Prolaris Value and Efficacy
This is a prospective study to measure the impact on first-line therapy of genomic testing of biopsy tissue from recently diagnosed treatment-naïve patients with early stage localized prostate cancer.
- Trial name
- P-PROVE (NCT03152448)
- Testing
- Prolaris
- Where
- 12 sites in United States
- Volunteers
- 1,511 people
- Sponsor
- Myriad Genetic Laboratories, Inc.
Bladder Cancer, Breast Cancer
OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors
RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Bladder Cancer, Breast Cancer, Kidney Cancer, Lung Cancer
- Trial name
- NCT00471432
- Testing
- custirsen sodium, docetaxel, pharmacological study
- Volunteers
- 40 people
- Sponsor
- NCIC Clinical Trials Group
Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer
RATIONALE: Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
- Trial name
- NCT00045006
- Testing
- vorinostat
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center